05 September, 2017
Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 15.90 on Wednesday. Teva Pharma had 85 analyst reports since July 21, 2015 according to SRatingsIntel. Zacks' sales averages are a mean average based on a survey of analysts that cover Teva Pharmaceutical Industries Limited. BTIG Research downgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Wednesday, November 16 to "Neutral" rating. The stock recorded a fall in short interest of -8.67% as of the latest report on August 15, 2017. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion.
Teva Pharmaceutical Industries Limited (TEVA)'s RSI (Relative Strength Index) is 19.67. The value of the investment in Teva Pharmaceutical Industries decreased from $60,474,000 to $29,157,000 decreasing 51.8% since the last quarter. Standpoint Research upgraded the shares of JEC in report on Tuesday, September 1 to "Buy" rating. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) earned "Hold" rating by Piper Jaffray on Thursday, August 3.
On August 7 the stock rating was downgraded from "Equal-Weight" to "Underweight" and a price target of $16.00 was set by Morgan Stanley. HSBC upgraded the stock to "Buy" rating in Monday, July 18 report. Jefferies maintained it with "Buy" rating and $69 target in Thursday, July 14 report. The institutional investor held 138,524 shares of the major pharmaceuticals company at the end of 2016Q4, valued at $5.02 million, down from 248,593 at the end of the previous reported quarter. Four equities research analysts have rated the stock with a sell rating, twenty have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. On August 7 the company was downgraded from "Equal-Weight" to "Underweight" and a price target of $16.00 was set by analysts at Morgan Stanley. Capital World Investors raised its stake in Teva Pharmaceutical Industries Limited by 41.9% in the second quarter. Next Financial Group, Inc expanded its ownership by buying 6,350 shares an increase of 150.3% from 03/31/2017 to 06/30/2017. Rwc Asset Management Llp bought 15,879 shares as the company's stock rose 3.89% with the market.
Teva Pharmaceutical Industries shares had a trading volume of 20,045K in the last trading session. PGGM Investments now owns 1,528,097 shares of the company's stock valued at $50,763,000 after buying an additional 163,292 shares during the period. GHP Investment Advisors Inc. now owns 13,353 shares of the company's stock valued at $444,000 after buying an additional 3,030 shares during the period. Capital Research Global Investors owns $1.21 billion in Teva Pharmaceutical Industries Limited, which represents roughly 7.63% of the company's market cap and approximately 12.83% of the institutional ownership. As of the end of the quarter Edge Asset Management, Inc had disposed of a total of 759,647 shares trimming its stake by 45.5%. Lapides Asset Mngmt Limited Liability Co holds 39,200 shares. Psagot Investment House Ltd sold 110,069 shares as the company's stock declined 15.11% while stock markets rallied. Teva Pharmaceutical Inds Ltd now has $16.41 billion valuation.
08/16/2017 - Teva Pharmaceutical Industries Limited was downgraded to "neutral" by analysts at Citigroup. The stock's 50-day moving average price is $23.15 and its 200 day moving average price is $29.75.
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 14th.
Investors sentiment increased to 0.64 in 2016 Q4. The ex-dividend date will be Friday August 25th, 2017. Teva Pharmaceutical Industries Limited's dividend payout ratio (DPR) is now -15.36%. 7,615 are owned by Winfield Associates Incorporated. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and worldwide trademark & copyright laws. The legal version of this article can be viewed at https://weekherald.com/2017/09/02/teva-pharmaceutical-industries-limited-teva-stake-reduced-by-airain-ltd.html.
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Firm operates through two divisions: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
